Coadministration of ribavirin and arenaviral entry inhibitor LHF-535 enhances antiviral benefit against authentic lassa virus

• A new strain of Lassa virus (LASV) was successfully isolated and characterized. • The combination of ribavirin and LHF-535 has been demonstrated to exhibit synergistic effects in inhibiting LASV. • The findings provide new directions for the development of antiviral drugs and vaccines for Lassa fever.